Elsubrutinib

Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor. The IC50 of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease[1].

Product Specifications

CAS Number

[1643570-24-4]

Product Name Alternative

ABBV-105

UNSPSC

12352005

Target

Btk

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/elsubrutinib.html

Purity

98.0

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=C([C@H]2CN(C(C=C)=O)CCC2)C3=C1NC=C3)N

Molecular Formula

C17H19N3O2

Molecular Weight

297.35

References & Citations

[1]Goess C, et al. ABBV-105, a selective and irreversible inhibitor of Bruton's tyrosine kinase, is efficacious in multiple preclinical models of inflammation [published correction appears in Mod Rheumatol. 2019 May;29 (3) :v]. Mod Rheumatol. 2019;29 (3) :510-522.